Published 6 days ago • loading... • Updated 5 days ago

CytoSite Bio Announces Agreement with Lantheus for Granzyme B Targeted PET Imaging Radiotracer for Immunotherapy Assessment

On March 26, 2025, Boston-based CytoSite Bio announced a global collaboration agreement with Lantheus Holdings, Inc. For the clinical development and potential commercialization of CytoSite's Phase 1 ready, Granzyme B-targeted Positron Emission Tomography imaging radiotracer.
CytoSite is developing novel radiopharmaceuticals, including a lead product that detects active Granzyme B, a key protein in tumor cell destruction by the immune system, with the goal of improving cancer immunotherapy.
This agreement grants Lantheus an exclusive option to license worldwide rights to CytoSite's novel imaging technology and allows for collaboration on clinical development, with CytoSite leading the initial phase.
Benjamin Larimer, PhD, Co-founder and CEO of CytoSite, stated, "We are excited to be partnering with Lantheus to bring Granzyme B PET imaging to the forefront," emphasizing the strategic nature and significant value potential of the collaboration.
This investigational PET imaging radiotracer has shown the potential to measure the early efficacy of immunotherapies, enabling faster decision-making, more efficient resource allocation, and potentially improved outcomes for patients with immuno-oncology, autoimmune-mediated, and inflammatory diseases, as noted by Co-founder Umar Mahmood, MD, PhD.

Insights by Ground AI

Does this summary seem wrong?

14 Articles

All

Left

Center

Right

Rutland Herald

+12 Reposted by 12 other sources

Center

CytoSite Bio Announces Agreement with Lantheus for Granzyme B Targeted PET Imaging Radiotracer for Immunotherapy Assessment

A global collaboration agreement has been signed for the development and commercialization of a Granzyme B-targeted Positron Emission Tomography (PET) imaging radiotracer.

6 days ago

Read Full Article

DAIC

GE Healthcare Launches New Cardiac PET Tracer

Flyrcado (flurpiridaz F18) injection is a unit dose positron emission tomography myocardial perfusion imaging agent for the detection of coronary artery disease. It is now available in select U.S. markets and has been granted traditional pass-through payment status by the U.S. Centers for Medicare and Medicaid.

5 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year